Ron Tilles, who stepped in as interim CEO of Turing Pharmaceuticals after Martin Shkreli's arrest, faced immense challenges managing the fallout from the company's notorious 5,000% price hike of Daraprim. Despite his limited knowledge of the pharmaceutical industry, Tilles worked to stabilize the company amid bankruptcy threats and public outrage, ultimately leading to its rebranding as Vyera Pharmaceuticals. Now a board member at Pyros Pharmaceuticals, Tilles emphasizes the importance of fair pricing in the industry, reflecting on the lessons learned from Turing's tumultuous past.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
